GlassScriptPhysician profile
Cameron Wood
NPI 1831683002
$1,214.55
in general payments reported to CMS, 2019-2025
21 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.68 · 2023: $294 · 2024: $468 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.68 |
| Education | $227.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $144.60 | 2023-2024 | Enhertu, Injectafer |
| Incyte Corporation | $123.50 | 2025 | Monjuvi |
| Astellas Pharma US INC | $120.15 | 2025 | Vyloy |
| Exelixis INC. | $116.75 | 2023-2024 | Cabometyx |
| Iovance Biotherapeutics, INC. | $100.08 | 2025 | Amtagvi |
| Sanofi-Aventis U.S. LLC | $83.99 | 2024 | |
| Pfizer INC. | $72.75 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $62.55 | 2023-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $51.85 | 2023 | |
| Celgene Corporation | $50.91 | 2024 | Reblozyl, Pomalyst |
| Foundation Medicine, INC. | $49.31 | 2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Genentech USA, INC. | $43.41 | 2022-2023 | Tecentriq |
| Amgen INC. | $34.83 | 2022-2023 | Kyprolis |
| Caris Mpi, INC. | $30.45 | 2025 | Mi Cancer Seek |
| Adaptive Biotechnologies Corporation | $22.85 | 2024 | Clonoseq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $21.08 | 2023 | Tukysa |
| Janssen Biotech, INC. | $19.86 | 2024 | Erleada |
| Abbvie INC. | $18.60 | 2024 | |
| Merck Sharp & Dohme LLC | $18.25 | 2023 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.49 | 2023 | Gilotrif |
| Glaxosmithkline, LLC. | $13.29 | 2024 | Ojjaara, Zejula, Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.